Intestinal Dysbiosis: Microbial Imbalance Impacts on Colorectal Cancer Initiation, Progression and Disease Mitigation.

Mary Garvey
Author Information
  1. Mary Garvey: Department of Life Science, Atlantic Technological University, F91 YW50 Sligo, Ireland. ORCID

Abstract

The human gastrointestinal tract houses a diverse range of microbial species that play an integral part in many biological functions. Several preclinical studies using germ-free mice models have demonstrated that the gut microbiome profoundly influences carcinogenesis and progression. Colorectal cancer appears to be associated with microbial dysbiosis involving certain bacterial species, including , pks+ , and , with virome commensals also disrupted in patients. A dysbiosis toward these pro-carcinogenic species increases significantly in CRC patients, with reduced numbers of the preventative species , , and evident. There is also a correlation between infection and CRC. , in particular, is strongly associated with CRC where it is associated with therapeutic resistance and poor outcomes in patients. The carcinogenic mode of action of pathogenic bacteria in CRC is a result of genotoxicity, epigenetic alterations, ROS generation, and pro-inflammatory activity. The aim of this review is to discuss the microbial species and their impact on colorectal cancer in terms of disease initiation, progression, and metastasis. The potential of anticancer peptides as anticancer agents or adjuvants is also discussed, as novel treatment options are required to combat the high levels of resistance to current pharmaceutical options.

Keywords

References

  1. Front Med (Lausanne). 2023 Aug 07;10:1225616 [PMID: 37614949]
  2. Anaerobe. 2020 Aug;64:102232 [PMID: 32634470]
  3. Pathogens. 2022 Apr 11;11(4): [PMID: 35456132]
  4. Gut. 2018 Apr;67(4):634-643 [PMID: 28539351]
  5. Antibiotics (Basel). 2022 Sep 28;11(10): [PMID: 36289982]
  6. Front Microbiol. 2022 Sep 26;13:999001 [PMID: 36225386]
  7. Front Pharmacol. 2023 Jun 09;14:1208044 [PMID: 37361202]
  8. Periodontol 2000. 2022 Jun;89(1):166-180 [PMID: 35244982]
  9. Cancer Prev Res (Phila). 2020 Jan;13(1):25-40 [PMID: 31771941]
  10. Indian J Gastroenterol. 2022 Feb;41(1):37-51 [PMID: 34989986]
  11. Malays J Med Sci. 2020 Jul;27(4):9-21 [PMID: 32863742]
  12. Gut. 2023 Feb;72(2):338-344 [PMID: 36604116]
  13. Eur J Clin Microbiol Infect Dis. 2023 Mar;42(3):305-322 [PMID: 36703031]
  14. Front Physiol. 2022 Nov 22;13:1040991 [PMID: 36483296]
  15. Front Microbiol. 2020 Oct 23;11:583378 [PMID: 33193224]
  16. J Natl Cancer Inst. 2020 May 1;112(5):516-524 [PMID: 31435679]
  17. Front Immunol. 2017 Nov 17;8:1553 [PMID: 29209314]
  18. Ann Gastroenterol. 2023 Jul-Aug;36(4):360-368 [PMID: 37396009]
  19. EMBO Mol Med. 2022 Aug 8;14(8):e15418 [PMID: 35758207]
  20. Biochem Biophys Rep. 2024 Feb 21;38:101665 [PMID: 38419757]
  21. Nat Commun. 2018 Nov 14;9(1):4781 [PMID: 30429469]
  22. Pharmaceutics. 2022 Jun 07;14(6): [PMID: 35745786]
  23. Front Endocrinol (Lausanne). 2023 Jul 25;14:1201198 [PMID: 37560308]
  24. Food Funct. 2021 Jan 7;12(1):340-350 [PMID: 33325946]
  25. J Transl Med. 2022 Jul 6;20(1):301 [PMID: 35794566]
  26. Microbiol Spectr. 2021 Dec 22;9(3):e0009021 [PMID: 34935421]
  27. Immun Inflamm Dis. 2022 Jun;10(6):e635 [PMID: 35634951]
  28. Front Oncol. 2021 Apr 15;11:626349 [PMID: 33937029]
  29. Genomics Proteomics Bioinformatics. 2023 Feb;21(1):84-96 [PMID: 35914737]
  30. Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1362-1372 [PMID: 34856773]
  31. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  32. Transl Oncol. 2023 Jan;27:101598 [PMID: 36512976]
  33. Pharmaceutics. 2022 Nov 01;14(11): [PMID: 36365177]
  34. Int J Mol Sci. 2023 Jan 11;24(2): [PMID: 36674985]
  35. BMC Med. 2022 Oct 3;20(1):323 [PMID: 36184594]
  36. Gut Microbes. 2022 Jan-Dec;14(1):2125734 [PMID: 36127825]
  37. Transl Res. 2023 Feb;252:45-52 [PMID: 36150688]
  38. Cancer Lett. 2020 Jan 28;469:456-467 [PMID: 31734354]
  39. Front Immunol. 2021 Nov 15;12:760451 [PMID: 34868002]
  40. Front Microbiol. 2023 Apr 18;14:1126808 [PMID: 37143538]
  41. J Gastrointest Cancer. 2023 Mar;54(1):165-170 [PMID: 35217999]
  42. Genes Dev. 2021 Jun;35(11-12):787-820 [PMID: 34074695]
  43. BMJ Open Gastroenterol. 2017 Jul 3;4(1):e000145 [PMID: 28944067]
  44. Asian Pac J Cancer Prev. 2022 Oct 01;23(10):3437-3442 [PMID: 36308369]
  45. Clin Transl Oncol. 2022 May;24(5):784-795 [PMID: 35000132]
  46. J Crohns Colitis. 2023 Oct 20;17(9):1504-1513 [PMID: 37052201]
  47. Cancers (Basel). 2022 Jun 10;14(12): [PMID: 35740541]
  48. Front Microbiol. 2020 Mar 19;11:405 [PMID: 32265865]
  49. J Microbiol. 2019 Jun;57(6):532-538 [PMID: 31054139]
  50. BMC Cancer. 2019 Sep 5;19(1):879 [PMID: 31488085]
  51. Cancer Med. 2023 Sep;12(18):19291-19300 [PMID: 37641475]
  52. Nat Rev Gastroenterol Hepatol. 2018 Dec;15(12):721-737 [PMID: 30185915]
  53. World J Gastrointest Surg. 2023 Apr 27;15(4):495-519 [PMID: 37206081]
  54. Molecules. 2022 Feb 20;27(4): [PMID: 35209215]
  55. Infect Dis Rep. 2023 Aug 14;15(4):454-469 [PMID: 37623050]
  56. Toxins (Basel). 2023 Jul 14;15(7): [PMID: 37505728]
  57. Signal Transduct Target Ther. 2022 Apr 23;7(1):135 [PMID: 35461318]
  58. Gut Microbes. 2021 Jan-Dec;13(1):1-14 [PMID: 33874856]
  59. Sci Rep. 2024 Feb 3;14(1):2819 [PMID: 38307921]
  60. Science. 2018 Feb 2;359(6375):592-597 [PMID: 29420293]
  61. Cell. 2017 Jul 27;170(3):548-563.e16 [PMID: 28753429]
  62. Front Immunol. 2022 Jul 15;13:961796 [PMID: 35911673]
  63. J Clin Invest. 2019 Mar 11;129(4):1699-1712 [PMID: 30855275]
  64. Biomolecules. 2015 Aug 11;5(3):1762-82 [PMID: 26270677]
  65. J Gastrointest Surg. 2023 Jul;27(7):1466-1472 [PMID: 36973501]
  66. Cancer Cell. 2022 Feb 14;40(2):185-200.e6 [PMID: 34951957]
  67. Microbiol Res. 2021 Nov 16;255:126921 [PMID: 34839170]
  68. Front Microbiol. 2022 Nov 03;13:945315 [PMID: 36406437]
  69. Cancers (Basel). 2021 Oct 09;13(20): [PMID: 34680186]
  70. Nutrients. 2023 May 11;15(10): [PMID: 37242159]
  71. Cureus. 2022 Jul 28;14(7):e27404 [PMID: 36046279]
  72. J Nutr Biochem. 2018 Jul;57:103-109 [PMID: 29694938]
  73. Int J Mol Sci. 2023 Dec 22;25(1): [PMID: 38203372]
  74. Biomedicines. 2023 Mar 01;11(3): [PMID: 36979726]
  75. BMC Cancer. 2020 Mar 14;20(1):217 [PMID: 32171282]
  76. Front Immunol. 2021 Feb 26;12:578386 [PMID: 33717063]
  77. J Exp Clin Cancer Res. 2020 Sep 29;39(1):202 [PMID: 32993749]
  78. J Microbiol Biotechnol. 2023 Jul 28;33(7):849-856 [PMID: 37100764]
  79. Neoplasia. 2022 Oct;32:100829 [PMID: 35933824]
  80. Clin Nutr. 2023 Feb;42(2):61-75 [PMID: 36502573]
  81. Oncogene. 2022 Jul;41(28):3599-3610 [PMID: 35680985]

Word Cloud

Created with Highcharts 10.0.0speciesCRCmicrobialcancerassociateddysbiosisalsopatientsprogressionColorectalresistancecolorectalanticanceroptionshumangastrointestinaltracthousesdiverserangeplayintegralpartmanybiologicalfunctionsSeveralpreclinicalstudiesusinggerm-freemicemodelsdemonstratedgutmicrobiomeprofoundlyinfluencescarcinogenesisappearsinvolvingcertainbacterialincludingpks+viromecommensalsdisruptedtowardpro-carcinogenicincreasessignificantlyreducednumberspreventativeevidentcorrelationinfectionparticularstronglytherapeuticpooroutcomescarcinogenicmodeactionpathogenicbacteriaresultgenotoxicityepigeneticalterationsROSgenerationpro-inflammatoryactivityaimreviewdiscussimpacttermsdiseaseinitiationmetastasispotentialpeptidesagentsadjuvantsdiscussednoveltreatmentrequiredcombathighlevelscurrentpharmaceuticalIntestinalDysbiosis:MicrobialImbalanceImpactsCancerInitiationProgressionDiseaseMitigationAMPsDNAdamageinflammation

Similar Articles

Cited By